logo
logo
10x Genomics, Inc.

10x Genomics, Inc.

NASDAQ•TXG
CEO: Dr. Serge Saxonov Ph.D.
セクター: Healthcare
業種: Medical - Healthcare Information Services
上場日: 2019-09-12
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
連絡先情報
6230 Stoneridge Mall Road, Pleasanton, CA, 94588-3260, United States
925-401-7300
www.10xgenomics.com
時価総額
$2.29B
PER (TTM)
-52.9
53.9
配当利回り
--
52週高値
$23.56
52週安値
$6.78
52週レンジ
68%
順位61Top 91.5%
2.0
F-Score
改良版 Piotroski 分析
8年ファンダメンタル
弱い • 2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2018-2025

財務ダッシュボード

Q4 2025 データ

売上高

$166.03M+0.00%
直近4四半期の推移

EPS

-$0.13+0.00%
直近4四半期の推移

フリーCF

$0.00+0.00%
直近4四半期の推移

2026 Annual 決算ハイライト

主なハイライト

Revenue Growth Driven by Settlements Revenue $642.8M, up 5.0%, driven by $44.1M non-recurring license and royalty income from settlements.
Net Loss Significantly Reduced Net loss narrowed sharply to $43.5M in 2025, a significant improvement from $182.6M loss reported in 2024.
Consumables Revenue Increased Consumables revenue increased 3.0% to $507.2M, led by Spatial consumables sales growing 19.0% year-over-year.
Strong Operating Cash Flow Operating cash flow provided $136.1M in 2025, reversing the prior year's $6.7M inflow, signaling better working capital management.

リスク要因

Continued Operating Losses Risk Accumulated deficit reached $1.5B; company expects operating losses to continue in the near term despite recent gains.
Instrument Sales Decline Instrument revenue fell 39% to $56.8M due to lower volume and expected price decreases across product lines.
Government Funding Dependency Business heavily dependent on U.S. academic and government funding, creating vulnerability to budget cuts and delays.
Intellectual Property Litigation Exposure Ongoing intellectual property litigation against Parse, Curio, and Illumina poses financial and operational risks.

見通し

Moderate 2026 Revenue Growth Expect revenues to moderately increase in 2026, excluding the significant non-recurring patent litigation settlement benefits.
Expense Management Focus Management plans R&D expense reduction of 10% and SG&A reduction of 8.2% for 2026 to manage spend.
Scale Bio Acquisition Integration Integrating Scale Bio acquisition completed in 2025; potential future contingent consideration payments up to $30.0M remain.
Capital Expenditure Planning Anticipating aggregate capital expenditures between $15M and $20M over next 12 months to support manufacturing and R&D.

同業比較

売上高 (TTM)

Teladoc Health, Inc.TDOC
$2.53B
-2.4%
Clover Health Investments, Corp.CLOV
$1.77B
+14.8%
Guardian Pharmacy Services, Inc.GRDN
$1.39B
+18.7%

粗利益率 (最新四半期)

Janux Therapeutics, Inc.JANX
95.0%
-5.0pp
GoodRx Holdings, Inc.GDRX
93.2%
-0.9pp
Nuvation Bio Inc.NUVB
74.5%
+182.9pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
TXG$2.29B-52.9-5.7%15.1%
ESTA$2.17B-26.6-253.8%77.1%
GRDN$2.12B51.724.7%8.7%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
2.3%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年5月6日
|
EPS:-
|
売上高:-
財務レポート
財務データ
全年度
  • Form 10-K - FY 2026

    会計期末: 2025年12月31日|提出日: 2026年2月13日|修正版データを参照
  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月7日|
    売上高: $149.00M-1.7%
    |
    EPS: $-0.22-26.7%
    予想を上回る
  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月8日|
    売上高: $172.91M+12.9%
    |
    EPS: $0.28-187.5%
    予想を上回る
  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月9日|
    売上高: $154.88M+9.8%
    |
    EPS: $-0.28-44.0%
    予想を上回る
  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月13日|
    売上高: $610.79M-1.3%
    |
    EPS: $-1.52+30.3%
    予想を下回る
  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年10月29日|
    売上高: $151.65M-1.3%
    |
    EPS: $-0.30-62.0%
    予想通り
  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月8日|
    売上高: $153.10M+4.3%
    |
    EPS: $-0.32-39.6%
    予想を上回る
  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年4月30日|
    売上高: $141.01M+5.0%
    |
    EPS: $-0.50+13.6%
    予想を上回る